Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
Immunological Reviews · 2024-01 · 321 (1) · 143-151
DOI: 10.1111/imr.13281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 11.10.2023. Verfasst von Carlos Luri-Rey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Cross-Priming, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Antigen cross‐priming of CD8 + T cells is a critical process necessary for the effective expansion and activation of CD8 + T cells endowed with the ability to recognize and destroy tumor cells. The cross‐presentation of tumor antigens to cross‐prime CD8 + T cells is mainly mediated, if not only, by a subset of professional antigen‐presenting cells termed type‐1 conventional dendritic cells (cDC1). The demise of malignant cells can be immunogenic if it occurs in the context of premortem stress. These ways of dying are termed immunogenic cell death (ICD) and are associated with biochemical features favoring cDC1 for the efficient cross‐priming of tumor antigens. Immunosurveillance and the success of immunotherapies heavily rely on the ability of cytotoxic immune cells, primarily CD8 + T cells and NK cells, to detect and eliminate tumor cells through mechanisms collectively known as cytotoxicity. Recent studies have revealed the significance of NK‐ and CTL‐mediated cytotoxicity as a prominent form of immunogenic cell death, resulting in mechanisms that promote and sustain antigen‐specific immune responses. This review focuses on the mechanisms underlying the cross‐presentation of antigens released during tumor cell killing by cytotoxic immune cells, with an emphasis on the role of cDC1 cells. Indeed, cDC1s are instrumental in the effectiveness of most immunotherapies, underscoring the significance of tumor antigen cross‐priming in contexts of immunogenic cell death. The notion of the potent immunogenicity of cell death resulting from NK or cytotoxic T lymphocyte (CTL)‐mediated cytotoxicity has far‐reaching implications for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
- Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
- Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
- Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.
ORCID-Profile: Javier Glez-Vaz, Ignacio Melero
Förderung
- Ministerio de Ciencia e Innovación
Zitieren
APA
Luri-Rey, C., Gomis, G., Glez-Vaz, J., Manzanal, A., Martinez Riaño, A., Rodriguez Ruiz, M. E., Teijeira, A., & Melero, I. (2024). Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming. Immunological Reviews, 321(1), 143-151. https://doi.org/10.1111/imr.13281
Vancouver
Luri-Rey C, Gomis G, Glez-Vaz J, Manzanal A, Martinez Riaño A, Rodriguez Ruiz ME, et al. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming. Immunological Reviews. 2024;321(1):143-151. doi:10.1111/imr.13281
BibTeX
@article{LuriRey2024,
author = {Luri-Rey, Carlos and Gomis, Gabriel and Glez-Vaz, Javier and Manzanal, Almudena and Martinez Riaño, Ana and Rodriguez Ruiz, Maria E and Teijeira, Alvaro and Melero, Ignacio},
title = {Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming},
journal = {Immunological Reviews},
year = {2024},
volume = {321},
number = {1},
pages = {143--151},
doi = {10.1111/imr.13281}
}
EUVIMED